- Introduced the first ddPCR device in Korea to provide high-quality clinical trial sample analysis services by increasing test accuracy
- Differentiate global lab services for cell and gene therapy clinical trials with cutting-edge technology
GCCL, a Korean clinical trial sample analysis company, has introduced Droplet Digital PCR devices (ddPCR) for the first time in the domestic clinical trial sample analysis industry, enhancing its capabilities in analyzing samples for cell and gene therapy clinical trials.
Currently, real-time PCR analysis is widespread in the field of clinical trial sample analysis for cell and gene therapy. However, the existing analysis methods have limitations such as relying on calibration reference standard samples for relative quantification, low analysis efficiency due to manual labor, and the necessity of separate analyses.
GCCL solves the existing problems by implementing automated ddPCR-based analysis. The newly introduced ddPCR device from Bio-Rad’s QX ONE Droplet Digital PCR, utilizes a different operating principle than conventional real-time PCR, enabling absolute quantitative analysis without the need for calibration standards. Moreover, stable PCR reactions allow detection in low-concentration samples and the automated devices have a very low rate of human error that could occur with manual labor.
Notably, GCCL is a leader in its field as it has the first clinical trial sample analysis experience for CAR-T therapy in Korea. Based on this, GCCL plans to provide ddPCR-based clinical trial sample analysis services through its newly established R&D unit.
GCCL’s Director of Operations for the Lab Operations division, Hee Joo Lee, mentioned, “The first implementation of the automated ddPCR device in the clinical trial sample analysis field will enable faster and more accurate results to help advance the success of cell and gene therapy drug development.” Furthermore, she added, “With the introduction of this device, GCCL has secured competitiveness not only in the domestic but also in the global market.” Lee concluded, “GCCL will position itself as a global central lab by providing superior clinical sample analysis for advanced biopharmaceuticals including cell and gene therapies, with ongoing investment and proven expertise in oncology, central nervous system (CNS) disorders, infectious disease, and in other various areas.”
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
